Increased awareness of the elevated levels of MetS-associated biomarkers, such as E-selectin may help early detection and management of individuals who are at risk for having MetS or its associated cardiovascular morbidity, particularly in individuals who already exhibit some clustered components of MetS. The gene discussed is SELE; the disease is metabolic syndrome.